Kaoru Tsuchiya

机构：Musashino Red Cross Hospital · ORCID：0000-0003-0436-5915

发表论文 259 篇 · 总被引 6734 次 · h-index 40

代表论文

• Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study (2025 · The Lancet · 被引 282)
• The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment (2025 · The Lancet · 被引 194)
• Depth and Duration of Response Are Associated with Survival in Patients with Unresectable Hepatocellular Carcinoma: Exploratory Analyses of IMbrave150 (2025 · Liver Cancer · 被引 16)
• Treatment response to durvalumab plus tremelimumab after progression with previous immune checkpoint inhibitor in unresectable hepatocellular carcinoma (2024 · Investigational New Drugs · 被引 13)
• Protocol of the IMPACT study: randomized, multicenter, phase 3 study evaluating the efficacy of immunotherapy (Atezolizumab) plus anti-VEGF therapy (Bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma (2025 · BMC Cancer · 被引 12)
• Proposal of discontinuation criteria of atezolizumab plus bevacizumab after curative conversion therapy for unresectable early-to-intermediate-stage hepatocellular carcinoma: a multicenter proof-of-concept study (2025 · Journal of Gastroenterology · 被引 12)